

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated 2 December 2015 issued by Chuangmei Pharmaceutical Co., Ltd. 創美藥業股份有限公司 (the “Company”).*

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

The Company makes this announcement pursuant to Section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong) and announces that the stabilisation period in connection with the Global Offering ended on 6 January 2016, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities.

This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the “U.S. Securities Act”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. There will be no public offer of securities in the United States.



CHUANGMEI PHARMACEUTICAL CO., LTD.*

創美藥業股份有限公司

(a joint stock limited liability company established in the People's Republic of China)

(Stock Code: 2289)

STABILISATION ACTIONS, END OF STABILISATION PERIOD AND LAPSE OF OVER-ALLOTMENT OPTION

STABILISATION ACTIONS AND END OF STABILISATION PERIOD

The Company announces that the stabilisation period in connection with the Global Offering ended on 6 January 2016, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. The Company was informed that stabilisation actions undertaken by Guotai Junan Securities (Hong Kong) Limited, the Stabilising Manager, during the stabilisation period involved:

- (1) Over-allocations of an aggregate of 4,200,000 H Shares in the International Offering, representing 15% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option); and

- (2) successive market purchases of an aggregate of 4,200,000 H Shares at a price in the range of HK\$7.47 to HK\$8.60 per H Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) during the stabilisation period, representing 15% of the Offer Shares initially offered under the Global Offering (before any exercise of the Over-allotment Option).

The Company was informed that the last purchase made by the Stabilising Manager on the market during the course of stabilisation period was on 15 December 2015 at the price of HK\$7.65 per H Share.

LAPSE OF OVER-ALLOTMENT OPTION

The Company further announces that the Over-allotment Option had not been exercised by the Sole Global Coordinator on behalf of the International Underwriters during the stabilisation period and the Over-allotment Option lapsed on 6 January 2016.

STABILISATION ACTIONS AND END OF STABILISATION PERIOD

The Company announces that the stabilisation period in connection with the Global Offering ended on 6 January 2016, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. The Company was informed that stabilisation actions undertaken by Guotai Junan Securities (Hong Kong) Limited, the Stabilising Manager, during the stabilisation period involved:

- (1) Over-allocations of an aggregate of 4,200,000 H Shares in the International Offering, representing 15% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option); and
- (2) successive market purchases of an aggregate of 4,200,000 H Shares at a price in the range of HK\$7.47 to HK\$8.60 per H Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) during the stabilisation period, representing 15% of the Offer Shares initially offered under the Global Offering (before any exercise of the Over-allotment Option).

The Company was informed that the last purchase made by the Stabilising Manager on the market during the course of stabilisation period was on 15 December 2015 at the price of HK\$7.65 per H Share.

LAPSE OF OVER-ALLOTMENT OPTION

The Company further announces that the Over-allotment Option had not been exercised by the Sole Global Coordinator on behalf of the International Underwriters during the stabilisation period and the Over-allotment Option lapsed on 6 January 2016.

The Company continues to comply with the public float requirements under Rule 8.08(1)(a) of the Listing Rules whereby at least 25% of the Company's total issued share capital must at all times be held by the public.

By order of the Board
Chuangmei Pharmaceutical Co., Ltd.*
Yao Chuanglong
Chairman

Hong Kong, 6 January 2016

As at the date of this announcement, the executive Directors are Mr. Yao Chuanglong, Ms. Zheng Yuyan, Mr. Fan Jianbo and Mr. Lin Zhixiong; the non-executive Director is Ms. You Zeyan; and the independent non-executive Directors are Mr. Wan Chi Wai Anthony, Mr. Zhou Tao and Mr. Guan Jian (also known as Guan Suzhe)

* *For identification purposes only*